RARB and breast carcinoma: According to the evidence presented in the meta‐analysis of RARB (Fang, Jian, et al., 2015) and GSTP1 (Gurioli et al., 2018), together with the results obtained in the present study, it is possible that methylated women in the control group may have a higher risk of developing breast cancer after menopause.